

Peer Review

Review of: "Incidence and Predictors of Ocular Hypertension After Intravitreal Injection of Bevacizumab Among Patients Attending KCMC Hospital, 2023–2024"

Nitin Kumar¹

1. Independent researcher

The article is well-written.

1. Why have the authors used a dosage of 0.1 ml of bevacizumab?
2. What is the rationale for only choosing bevacizumab for the study? Do other anti-VEGFs also produce an IOP increase after injections?
3. The risk of IOP increase after anti-VEGFs is well known; what new information does this study add?

Declarations

Potential competing interests: No potential competing interests to declare.